Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions.

He Y, Rhodes SD, Chen S, Wu X, Yuan J, Yang X, Jiang L, Li X, Takahashi N, Xu M, Mohammad KS, Guise TA, Yang FC.

PLoS One. 2012;7(11):e46900. doi: 10.1371/journal.pone.0046900. Epub 2012 Nov 7.

2.

Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.

Yang FC, Chen S, Robling AG, Yu X, Nebesio TD, Yan J, Morgan T, Li X, Yuan J, Hock J, Ingram DA, Clapp DW.

J Clin Invest. 2006 Nov;116(11):2880-91. Epub 2006 Oct 19.

3.

Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1.

Yan J, Chen S, Zhang Y, Li X, Li Y, Wu X, Yuan J, Robling AG, Kapur R, Chan RJ, Yang FC.

Hum Mol Genet. 2008 Apr 1;17(7):936-48. Epub 2007 Dec 18. Erratum in: Hum Mol Genet. 2008 Jun 15;17(12):1876. Karpur, Reuben [corrected to Kapur, Reuben].

PMID:
18089636
4.

Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.

Sharma R, Wu X, Rhodes SD, Chen S, He Y, Yuan J, Li J, Yang X, Li X, Jiang L, Kim ET, Stevenson DA, Viskochil D, Xu M, Yang FC.

Hum Mol Genet. 2013 Dec 1;22(23):4818-28. doi: 10.1093/hmg/ddt333. Epub 2013 Jul 17.

5.

Anti-c-Fms antibody inhibits lipopolysaccharide-induced osteoclastogenesis in vivo.

Kimura K, Kitaura H, Fujii T, Hakami ZW, Takano-Yamamoto T.

FEMS Immunol Med Microbiol. 2012 Mar;64(2):219-27. doi: 10.1111/j.1574-695X.2011.00888.x. Epub 2011 Dec 5.

6.

Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model.

Li H, Liu Y, Zhang Q, Jing Y, Chen S, Song Z, Yan J, Li Y, Wu X, Zhang X, Zhang Y, Case J, Yu M, Ingram DA, Yang FC.

Pediatr Res. 2009 Jun;65(6):613-8. doi: 10.1203/PDR.0b013e3181a1c607.

PMID:
19247213
7.

The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.

Watanabe K, Hirata M, Tominari T, Matsumoto C, Fujita H, Yonekura K, Murphy G, Nagase H, Miyaura C, Inada M.

J Biol Chem. 2016 Sep 30;291(40):20891-20899. Epub 2016 Aug 18.

8.

Role of IGF-I signaling in regulating osteoclastogenesis.

Wang Y, Nishida S, Elalieh HZ, Long RK, Halloran BP, Bikle DD.

J Bone Miner Res. 2006 Sep;21(9):1350-8.

9.

Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis.

Baud'huin M, Renault R, Charrier C, Riet A, Moreau A, Brion R, Gouin F, Duplomb L, Heymann D.

J Pathol. 2010 May;221(1):77-86. doi: 10.1002/path.2684.

PMID:
20191615
10.

A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.

Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M, Yoneda T, Isoe T.

Mol Cancer Ther. 2006 Nov;5(11):2634-43.

11.

Regulation of osteoclast apoptosis and motility by small GTPase binding protein Rac1.

Fukuda A, Hikita A, Wakeyama H, Akiyama T, Oda H, Nakamura K, Tanaka S.

J Bone Miner Res. 2005 Dec;20(12):2245-53. Epub 2005 Aug 22.

12.

Activated c-Fms recruits Vav and Rac during CSF-1-induced cytoskeletal remodeling and spreading in osteoclasts.

Sakai H, Chen Y, Itokawa T, Yu KP, Zhu ML, Insogna K.

Bone. 2006 Dec;39(6):1290-301. Epub 2006 Sep 1.

PMID:
16950670
13.

c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.

Paniagua RT, Chang A, Mariano MM, Stein EA, Wang Q, Lindstrom TM, Sharpe O, Roscow C, Ho PP, Lee DM, Robinson WH.

Arthritis Res Ther. 2010;12(1):R32. doi: 10.1186/ar2940. Epub 2010 Feb 24.

14.

Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.

Rhodes SD, Yang H, Dong R, Menon K, He Y, Li Z, Chen S, Staser KW, Jiang L, Wu X, Yang X, Peng X, Mohammad KS, Guise TA, Xu M, Yang FC.

J Bone Miner Res. 2015 Oct;30(10):1840-51. doi: 10.1002/jbmr.2538. Epub 2015 May 21.

15.

Erk1 positively regulates osteoclast differentiation and bone resorptive activity.

He Y, Staser K, Rhodes SD, Liu Y, Wu X, Park SJ, Yuan J, Yang X, Li X, Jiang L, Chen S, Yang FC.

PLoS One. 2011;6(9):e24780. doi: 10.1371/journal.pone.0024780. Epub 2011 Sep 22.

16.

Neuromedin B and its receptor silencing suppresses osteoclast generation by modulating precursor proliferation via M-CSF/c-Fms/D-type cyclins.

Yeo CE, Kang WY, Seong SJ, Cho S, Lee HW, Yoon YR, Kim HJ.

Exp Cell Res. 2017 Oct 1;359(1):112-119. doi: 10.1016/j.yexcr.2017.08.003. Epub 2017 Aug 3.

PMID:
28780306
17.

Engineering a monomeric variant of macrophage colony-stimulating factor (M-CSF) that antagonizes the c-FMS receptor.

Zur Y, Rosenfeld L, Bakhman A, Ilic S, Hayun H, Shahar A, Akabayov B, Kosloff M, Levaot N, Papo N.

Biochem J. 2017 Jul 20;474(15):2601-2617. doi: 10.1042/BCJ20170276.

PMID:
28655719
18.

2-(trimethylammonium) ethyl (R)-3-methoxy-3-oxo-2-stearamidopropyl phosphate suppresses osteoclast maturation and bone resorption by targeting macrophage-colony stimulating factor signaling.

Park SJ, Park DR, Bhattarai D, Lee K, Kim J, Bae YS, Lee SY.

Mol Cells. 2014 Aug;37(8):628-35. doi: 10.14348/molcells.2014.0190. Epub 2014 Aug 19.

19.

Role of c-Src in cellular events associated with colony-stimulating factor-1-induced spreading in osteoclasts.

Insogna K, Tanaka S, Neff L, Horne W, Levy J, Baron R.

Mol Reprod Dev. 1997 Jan;46(1):104-8. Review.

PMID:
8981371
20.

Hyperactivation of mTOR critically regulates abnormal osteoclastogenesis in neurofibromatosis Type 1.

Ma J, Li M, Hock J, Yu X.

J Orthop Res. 2012 Jan;30(1):144-52. doi: 10.1002/jor.21497. Epub 2011 Jul 11.

Supplemental Content

Support Center